Adamas Pharmaceuticals Inc (NASDAQ:ADMS) shares hit a new 52-week low during trading on Thursday . The stock traded as low as $9.03 and last traded at $9.58, with a volume of 25498 shares traded. The stock had previously closed at $10.14.
ADMS has been the subject of several recent analyst reports. HC Wainwright set a $45.00 price objective on Adamas Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, September 17th. ValuEngine lowered Adamas Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 28th. Mizuho reissued a “buy” rating and set a $75.00 price objective on shares of Adamas Pharmaceuticals in a report on Friday, August 17th. Cowen set a $30.00 price objective on Adamas Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, November 1st. Finally, Zacks Investment Research raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 6th. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company’s stock. Adamas Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $32.13.
The company has a market capitalization of $277.18 million, a PE ratio of -2.52 and a beta of 1.43. The company has a quick ratio of 8.74, a current ratio of 8.95 and a debt-to-equity ratio of 1.01.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.34) by $0.12. The business had revenue of $10.61 million during the quarter, compared to analyst estimates of $10.10 million. Adamas Pharmaceuticals had a negative return on equity of 106.74% and a negative net margin of 617.27%. Analysts predict that Adamas Pharmaceuticals Inc will post -5.23 earnings per share for the current fiscal year.
In other news, CEO Gregory T. Went bought 3,850 shares of the business’s stock in a transaction on Wednesday, November 7th. The stock was acquired at an average price of $12.98 per share, with a total value of $49,973.00. Following the completion of the purchase, the chief executive officer now directly owns 182,610 shares in the company, valued at $2,370,277.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Alfred G. Merriweather sold 1,665 shares of the company’s stock in a transaction that occurred on Friday, September 21st. The stock was sold at an average price of $19.18, for a total value of $31,934.70. Following the completion of the sale, the chief financial officer now directly owns 25,460 shares of the company’s stock, valued at approximately $488,322.80. The disclosure for this sale can be found here. 24.60% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Pacer Advisors Inc. bought a new stake in Adamas Pharmaceuticals in the third quarter valued at approximately $104,000. Tower Research Capital LLC TRC bought a new stake in Adamas Pharmaceuticals in the third quarter valued at approximately $162,000. Metropolitan Life Insurance Co. NY lifted its position in Adamas Pharmaceuticals by 43.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 7,606 shares of the specialty pharmaceutical company’s stock valued at $196,000 after purchasing an additional 2,293 shares during the last quarter. State Board of Administration of Florida Retirement System bought a new stake in Adamas Pharmaceuticals in the second quarter valued at approximately $203,000. Finally, GSA Capital Partners LLP bought a new stake in Adamas Pharmaceuticals in the second quarter valued at approximately $212,000. 94.01% of the stock is owned by institutional investors and hedge funds.
Adamas Pharmaceuticals Company Profile (NASDAQ:ADMS)
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Recommended Story: Compound Interest and Why It Matters When Investing
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.